

# R-3327 AT.2 cell line

**Catalogue number:** 156411

**Sub-type:**

**Images:**

## Contributor

**Inventor:** John Isaacs

**Institute:** Johns Hopkins University

**Images:**

## Tool details

**\*FOR RESEARCH USE ONLY**

**Name:** R-3327 AT.2 cell line

**Alternate name:**

**Class:**

**Conjugate:**

**Description:** AT-2 originates from the spontaneous tumor (R3327) of the prostate identified by W.F. Dunning in a 22 month-old inbred Copenhagen male rat in 1961. R3327 has been maintained by continuous serial passage in rats for many years. AT-2 was identified in 1981 and was the second of such anaplastic tumors to arise. Following subcutaneous transplantation in syngeneic male rats, AT-2 forms solid sheets of malignant cells with no indication of glandular function. These tumors are androgen-independent and grow continuously with a doubling time of approximately 2.5 days. AT-2 exhibits a low to moderate metastatic ability (<20% of rats inoculated sub-cutaneously develop distant metastases). The AT-2 subline can be used to study the effects of various types of cancer therapies on prostate cells.

**Purpose:**

**Parental cell:**

**Organism:**

**Tissue:**

**Model:** Cancer Model

**Gender:**

**Isotype:**

**Reactivity:**

**Selectivity:**

**Host:**

**Immunogen:**

**Immunogen UNIPROT ID:**

**Sequence:**

**Growth properties:**  
**Production details:**  
**Formulation:**  
**Recommended controls:**  
**Bacterial resistance:**  
**Selectable markers:**  
**Additional notes:**

## Target details

**Target:** Androgen-independent anaplastic tumors

**Target alternate names:**

**Target background:**

**Molecular weight:**

**Ic50:**

## Applications

**Application:**  
**Application notes:**

## Handling

**Format:** Frozen  
**Concentration:**  
**Passage number:**  
**Growth medium:**  
**Temperature:**  
**Atmosphere:**  
**Volume:**  
**Storage medium:**  
**Storage buffer:**  
**Storage conditions:**  
**Shipping conditions:** Dry ice

## Related tools

**Related tools:**

## References

**References:** Musialik et al. 2013. Oncol Rep. 29(5):1789-96. PMID: 23467722. ; Isaacs et al. 1981. Invest Urol. 19(1):20-3. PMID: 7251319.

CancerTools.org